Status:
NOT_YET_RECRUITING
Screening and Intervention of MASLD in Children
Lead Sponsor:
Ningbo No. 1 Hospital
Collaborating Sponsors:
Peking University
Conditions:
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Children
Eligibility:
All Genders
7-11 years
Phase:
NA
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) in children and adolescents has recently been renamed metabolic dysfunction-associated steatotic liver disease (MASLD). It has become one of the leading chron...
Eligibility Criteria
Inclusion
- parents agree and support their children's weight loss, and students and parents have informed consent;
- students in two to four grade aged 7 and 11 years old;
- students with WHtR \> 0.48.
Exclusion
- medical history of heart disease, hypertension, diabetes, tuberculosis, asthma, virus hepatitis or nephritis;
- obesity caused by endocrine diseases or side effects of drugs;
- abnormal physical development like dwarfism or gigantism;
- physical deformity such as severe scoliosis, pectus carinatum, limp, obvious O-leg or X-leg;
- inability to participate in school sport activities;
- a loss in weight by vomiting or taking drugs during the past 3 months.
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2027
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT06905795
Start Date
April 1 2025
End Date
May 31 2027
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China, 315010